The KLF3 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T lymphoblastoid cell line, engineered to disrupt KLF3 gene expression. This pooled format provides a heterogeneous loss-of-function model that avoids the potential biases of single-cell clonal selection, making it suitable for studying the collective effects of KLF3 ablation in T lymphocyte biology. The product is designed for functional genomics, signal transduction, and cancer research applications where a knockout of the transcriptional repressor KLF3 is desired.
Jurkat cells are an extensively characterized T cell acute lymphoblastic leukemia (T-ALL) line originally derived from a patient with T-ALL. They serve as a well-established model system for investigating T cell receptor signaling, apoptosis, and leukemogenesis. The T lymphoblastoid nature of Jurkat cells provides a physiologically relevant context for examining the role of hematopoietic transcriptional regulators such as KLF3 in T cell development and malignant transformation.
KLF3 functions as a transcriptional repressor by binding to CACCC box motifs in target gene promoters and recruiting co-repressor complexes containing CBP/p300, HDAC1, and CtBP. It is regulated by TGF-beta and E2F1, and cooperates with GATA1 and FOG1 in hematopoietic proliferation and differentiation. Downstream targets include CCND1, CDKN1A, and embryonic globin genes, linking KLF3 to cell cycle arrest and erythroid development. Through these interactions, KLF3 integrates TGF-beta signaling and cell cycle control.
In the Jurkat T-ALL background, disruption of KLF3 enables investigation of its role in T cell signaling and drug sensitivity. Since KLF3 controls hematopoietic proliferation and differentiation, knockout cells can be used to study leukemia cell survival and therapeutic resistance, relevant to myelodysplastic syndrome, anemia, and acute myeloid leukemia.
Researchers can employ these polyclonal knockout cells in a wide range of assays, including Western blotting and RT-qPCR for expression analysis, flow cytometry for phenotypic profiling, and functional assays such as apoptosis, proliferation, migration, and drug sensitivity studies. Additional applications include ChIP-qPCR to assess KLF3-target interactions, RNA-seq for transcriptome-wide profiling, and reporter assays to dissect signaling pathways. For further inquiries or technical support, please contact Ascent Research.
